Considerations for biomarker strategies in clinical trials investigating tau-targeting therapeutics for Alzheimer's disease
| dc.contributor.author | Penny, Lewis K | |
| dc.contributor.author | Lofthouse, Richard | |
| dc.contributor.author | Arastoo, Mohammad | |
| dc.contributor.author | Porter, Andy | |
| dc.contributor.author | Palliyil, Soumya | |
| dc.contributor.author | Harrington, Charles R | |
| dc.contributor.author | Wischik, Claude M | |
| dc.contributor.institution | University of Aberdeen.Institute of Medical Sciences | en |
| dc.contributor.institution | University of Aberdeen.Medicine, Medical Sciences & Nutrition | en |
| dc.contributor.institution | University of Aberdeen.Medical Sciences | en |
| dc.contributor.institution | University of Aberdeen.Microbiology and Immunity | en |
| dc.contributor.institution | University of Aberdeen.Neuroscience | en |
| dc.contributor.institution | University of Aberdeen.Farr Aberdeen | en |
| dc.contributor.institution | University of Aberdeen.Applied Medicine | en |
| dc.date.accessioned | 2024-06-20T10:54:01Z | |
| dc.date.available | 2024-06-20T10:54:01Z | |
| dc.date.issued | 2024-05-21 | |
| dc.description.status | Peer reviewed | en |
| dc.format.extent | 14 | |
| dc.format.extent | 1172528 | |
| dc.identifier | 289742215 | |
| dc.identifier | 650d3976-8395-42d1-b4d8-0b407542051c | |
| dc.identifier | 38773569 | |
| dc.identifier | 85193812623 | |
| dc.identifier.citation | Penny, L K, Lofthouse, R, Arastoo, M, Porter, A, Palliyil, S, Harrington, C R & Wischik, C M 2024, 'Considerations for biomarker strategies in clinical trials investigating tau-targeting therapeutics for Alzheimer's disease', Translational neurodegeneration, vol. 13, 25. https://doi.org/10.1186/s40035-024-00417-w | en |
| dc.identifier.doi | 10.1186/s40035-024-00417-w | |
| dc.identifier.issn | 2047-9158 | |
| dc.identifier.other | PubMedCentral: PMC11107038 | |
| dc.identifier.other | ORCID: /0000-0002-0805-4949/work/162251788 | |
| dc.identifier.other | ORCID: /0000-0003-2250-3920/work/173415878 | |
| dc.identifier.uri | https://hdl.handle.net/2164/23668 | |
| dc.identifier.vol | 13 | en |
| dc.language.iso | eng | |
| dc.relation.ispartof | Translational neurodegeneration | en |
| dc.subject | Substantive connection via an eligible employment contract | en |
| dc.subject | Alzheimer Disease/metabolism | en |
| dc.subject | Humans | en |
| dc.subject | tau Proteins/metabolism | en |
| dc.subject | Biomarkers/analysis | en |
| dc.subject | Clinical Trials as Topic/methods | en |
| dc.title | Considerations for biomarker strategies in clinical trials investigating tau-targeting therapeutics for Alzheimer's disease | en |
| dc.type | Journal item | en |
Files
Original bundle
1 - 1 of 1
